Dr. Dunbar is interested in atherogenic dyslipidemia and its treatment, and has particular expertise in the mechanism of action and adverse effects of nicotinic acid (niacin). He has developed sophisticated objective techniques to quantify the physical stigmata of flushing from niacin. He combines these techniques with laboratory pharmacodynamic studies to elucidate the integrated physiology of the response to niacin.
Dr. Dunbar specializes in the treatment of cholesterol disorders, and practices in the Preventive Cardiology Clinic at the Pereleman Center for Advanced Medicine
Goldberg RB, Bittner VA, Dunbar RL, Fleg JL, Grunberger G, Guyton JR, Leiter LA, McBride R, Robinson JG, Simmons DL, Wysham C, Xu P, Boden WE: Effects of Extended Release Niacin added to Simvastatin/Ezetemibe on Glucose and Insulin values in AIM HIGH American Journal of Medicine 129(7), July 2016 Notes: [Accepted for Publication]
Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, Graham MJ, Hughes SG, Yu R, Singleton W, Baker BF, Bhanot S, Crooke RM: Antisense Mediated Lowering of Plasma Apolipoprotein C‐III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes. Journal of Clinical Lipidology 10(3), May 2016 Notes: [Accepted as Oral Presentation to the 2016 National Lipid Association Scientific Sessions, New Orleans, May 19-22]
Goel H, Dunbar RL: Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin Mimetics. Curr Atheroscler Rep 18(4): 17, April 2016.
Reyes-Soffer G, Millar JS, Ngai C, Jumes P, Coromilas E, Asztalos B, Johnson-Levonas AO, Wagner JA, Donovan JS, Karmally W, Ramakrishnan R, Holleran S, Thomas T, Dunbar RL, deGoma EM, Rafeek H, Baer AL, Liu Y, Lassman ME, Gutstein DE, Rader DJ, Ginsberg HN : Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein. Arterioscler Thromb Vasc Biol 36, March 2016.
Dunbar RL, Goel H: Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin Regimens. Curr Atheroscler Rep 18(2): 11, February 2016.
Dunbar RL, Nicholls SJ, Maki KC, Roth EM, Orloff DG, Curcio D, Johnson J, Kling D, Davidson MH: Effects of Omega-3 Carboxylic Acids on Lipoprotein Particles and Other Cardiovascular Risk Markers in High-Risk Statin-Treated Patients with Residual Hypertriglyceridemia: A Randomized, Controlled, Double-blind Trial. Lipids Health Dis 14(98): 14, September 2015.
Millar JS, Reyes-Soffer G, Jumes P, Dunbar RL, deGoma EM, Rafeek H, Baer AL, Pollan L, Tohyama J, Liu Y, Johnson-Levonas AO, Wagner JA, Donovan DS, Karmally W, Ramakrishnan R, Holleran S, Obunike J, Lassman ME, Gutstein DE, Ginsberg HN, Rader DJ: Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. J Clin Invest 125(6): 2510-2522, June 2015.
deGoma EM, Salavati A, Shinohara RT, Saboury B, Pollan L, Schoen M, Torigian DA, Mohler ER, Dunbar RL, Litt HI, Woo J, Rader DJ, Alavi A, Mehta NN: A Pilot Trial to Examine the Effect of High-Dose Niacin on Arterial Wall Inflammation Using Fluorodeoxyglucose Positron Emission Tomography. Acad Radiol 22(5): 600-609, May 2015.
Khera AV, Qamar A, Reilly MP, Dunbar RL, Rader DJ: Effects of Niacin, Statin, and Fenofibrate on Circulating PCSK9 Levels in Patients with Dyslipidemia. American Journal of Cardiology 115(2): 178-182, January 2015.
Song W, Stubbe J, Ricciotti E, Dunbar RL, Rader DJ, FitzGerald GA: Systemic Eicosanoid and Cytokine Response to Niacin: Implications in HPS2-THRIVE Trial and Beyond [Poster Presentation] Journal of Clinical Lipidology 8(3): 309, June 2014 Notes: National Lipid Association 2014 Annual Scientific Sessions, May 1-4, 2014, Orlando, FL.
back to top
Last updated: 04/29/2016
The Trustees of the University of Pennsylvania